NCT03153384

Brief Summary

To evaluate the performance of a single high volume blood culture sampling strategy versus the actually used multiple sampling strategy for the diagnosis and categorization of infective endocarditis according to the Duke-Li classification in a Population of adults suspected of infective endocarditis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
269

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2017

Longer than P75 for all trials

Geographic Reach
1 country

8 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 5, 2017

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 15, 2017

Completed
6 months until next milestone

Study Start

First participant enrolled

November 11, 2017

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 5, 2022

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 8, 2022

Completed
Last Updated

March 19, 2024

Status Verified

March 1, 2024

Enrollment Period

4.5 years

First QC Date

May 5, 2017

Last Update Submit

March 18, 2024

Conditions

Keywords

DiagnosisBlood Culture

Outcome Measures

Primary Outcomes (1)

  • Compared performance of a single high volume blood culture vs. multiple blood culture of usual volume for the diagnosis of infective endocarditis

    Sensitivity/Specificity/Accuracy of positive bloodculture sets vs. final diagnosis assessed by the medical team (gold standard)

    At the end of the hospitalization, or at the time of death if occurred during hospitalization; i.e. an average of 6 weeks after the inclusion

Secondary Outcomes (3)

  • Diagnostic performance of the single high volume blood culture for the diagnosis of infective endocarditis

    At the end of the hospitalization, or at the time of death if occurred during hospitalization; i.e. an average of 6 weeks after the inclusion

  • Measuring the nursing time required for both sampling methods.

    At T0, i.e. at the inclusion of the patient

  • Diagnosis of infective endocarditis: confirmed, possible or excluded

    At the end of the hospitalization, or at the time of death if occurred during hospitalization; i.e. an average of 6 weeks after the inclusion

Study Arms (1)

one both experimental and control arm

Each patient experiences two methods of blood cultures.

Procedure: Blood Culture

Interventions

Blood CulturePROCEDURE

For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).

one both experimental and control arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Hospitalized adult patients suspected of infective endocarditis

You may qualify if:

  • Patients older than 18 years
  • Suspected endocarditis: Patients with Duke-Li-ESC 2015 classification as a major morphological criterion or at least two minor criteria, other than a microbiological criterion, will be considered suspicious of infectious endocarditis.

You may not qualify if:

  • Antibiotherapy adapted to a situation of endocarditis, introduced more than 24 hours or stopped for less than 7 days in case of therapeutic window.
  • State of consciousness not allowing loyal information.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Hôpital Nord Franche Comté

Belfort, 90000, France

Location

Centre Hospitalier universitaire de Besançon

Besançon, 25000, France

Location

Centre Hospitalier universitaire de Dijon

Dijon, 25000, France

Location

Centre hospitalier Universitaire de Nancy

Nancy, 54511, France

Location

Hopital BIchat Claude Bernard

Paris, 75018, France

Location

Centre Hospitalier Universitaire de Reims

Reims, 51100, France

Location

Centre Hospitalier Univesitaire de Rennes

Rennes, 35000, France

Location

Hôpitaux Civils de Strasbourg

Strasbourg, 67000, France

Location

Related Publications (4)

  • Arendrup M, Jensen IP, Justesen T. Diagnosing bacteremia at a Danish hospital using one early large blood volume for culture. Scand J Infect Dis. 1996;28(6):609-14. doi: 10.3109/00365549609037969.

    PMID: 9060065BACKGROUND
  • Dargere S, Parienti JJ, Roupie E, Gancel PE, Wiel E, Smaiti N, Loiez C, Joly LM, Lemee L, Pestel-Caron M, du Cheyron D, Verdon R, Leclercq R, Cattoir V; UBC study group. Unique blood culture for diagnosis of bloodstream infections in emergency departments: a prospective multicentre study. Clin Microbiol Infect. 2014 Nov;20(11):O920-7. doi: 10.1111/1469-0691.12656. Epub 2014 Jun 14.

    PMID: 24766148BACKGROUND
  • The 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015 Nov 21;36(44):3036-7. doi: 10.1093/eurheartj/ehv488.

    PMID: 26590409BACKGROUND
  • Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, Bashore T, Corey GR. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000 Apr;30(4):633-8. doi: 10.1086/313753. Epub 2000 Apr 3.

    PMID: 10770721BACKGROUND

MeSH Terms

Conditions

BacteremiaEndocarditisDisease

Interventions

Blood Culture

Condition Hierarchy (Ancestors)

Bacterial InfectionsBacterial Infections and MycosesInfectionsSepsisSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsHeart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Microbiological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative Techniques

Study Officials

  • François Goehringer, MD

    Centre Hospitalier Universitaire de Nancy, Nancy, France

    PRINCIPAL INVESTIGATOR
  • Xavier Duval, MD PhD

    APHP, Hôpital Bichat Claude Bernard, Paris, France.

    STUDY CHAIR
  • Christine Selton-Suty, MD

    Centre Hospitalier Universitaire de Nancy, Nancy, France

    STUDY CHAIR
  • Nejla Aissa, MD

    Centre Hospitalier Universitaire de Nancy, Nancy, France

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
6 Weeks
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

May 5, 2017

First Posted

May 15, 2017

Study Start

November 11, 2017

Primary Completion

May 5, 2022

Study Completion

July 8, 2022

Last Updated

March 19, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations